Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia

Top-line data provide key information for the design of a Phase 3 study CELEBRATION, Fla., March 26, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. ZVRA (Zevra, or the Company) a rare disease therapeutics company, today announced top-line data from its placebo-controlled, double-blind Phase 2…#celebration #fla #zevra #phase2 #nct05668754 #kp1077 #zevraphase2 #ih #christopherdrake #phd
Source: Reuters: Health - Category: Consumer Health News Source Type: news